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Original Article
Curative resection for lung cancer in octogenarians is justified
Michaela Tutic-Horn1*, Franco Gambazzi2*, Gaetano Rocco3, Monique Mosimann2, Didier Schneiter1, 
Isabelle Opitz1, Nono Martucci3, Sven Hillinger1, Walter Weder1, Wolfgang Jungraithmayr1,4
1Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; 2Division of Thoracic Surgery, Cantonal Hospital Aarau, 
Aarau, Switzerland; 3Division of Thoracic Surgery, University Hospital Naples, Naples, Italy; 4Department of Thoracic Surgery, Medical University 
Brandenburg, Germany
Contributions: (I) Conception and design: M Tutic-Horn; (II) Administrative support: All authors; (III) Provision of study materials or patients: All 
authors; (IV) Collection and assembly of data: M Tutic-Horn, F Gambazzi; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: 
All authors; (VII) Final approval of manuscript: All authors.
*These authors contributed equally to this study.
Correspondence to: Wolfgang Jungraithmayr, MD, PhD. Department of Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, 
Switzerland. Email: wolfgang.jungraithmayr@usz.ch.
Background: Due to an increased life expectancy in a healthy aging population and a progressive incidence 
of lung cancer, curative pulmonary resections can be performed even in octogenarians. The present study 
aims to investigate whether surgery is justified in patients reaching the age of 80 years and older who 
undergo resection for non-small cell lung cancer (NSCLC). 
Methods: In this retrospective multi-centre analysis, the morbidity, mortality and long-term survival of 
88 patients (24 females) aged ≥80 who underwent complete resection for lung cancer between 2000 and 
2013 were analysed. Only fit patients with few comorbidities, low cardiopulmonary risk, good quality of 
life and a life expectancy of at least 5 years were included.
Results: Curative resections from three thoracic surgery centres included 61 lobectomies, 9 bilobectomies, 
6 pneumonectomies and 12 segmentectomies or wide wedge resections with additional systematic mediastinal 
lymphadenectomy in all cases. Final histology revealed squamous cell carcinoma [33], adenocarcinoma 
[41], large cell carcinoma [5] or other histological types [9]. Lung cancer stage distribution was 0 [1], I [53],  
II [17] and IIIA [14]. The overall 90-day mortality was 1.1%. The median hospitalisation and chest drainage 
times were 10 days (range, 5–27 days) and 5 days (range, 0–17 days), respectively. Thirty-six patients were 
complication-free (41%). In particular, pulmonary complications occurred in 25 patients (28%). In addition, 
23 patients (26%) developed cardiovascular complications requiring medical intervention, while 24 patients 
(27%) had cerebrovascular complications, urinary tract infection and others. The median survival time was 
51 months (range, 1–110 months), and the 5-year overall survival reached 45% without significance between 
tumour stages. 
Conclusions: Curative lung resections in selected octogenarians can be safely performed up to 
pneumonectomy for all tumour stages with a perioperative mortality, morbidity, and 5-year survival rate 
comparable to younger cohorts.
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Introduction
With an increasing life expectancy in western countries, 
the mean age of the population is increasing as well as the 
subgroup of individuals aged >80 years (1,2), who also suffer 
increasingly from lung cancer (3,4). Lung cancer is the 
leading cancer and second leading cause of cancer mortality in 
men and women, respectively, among women worldwide (5). 
Moreover, the diagnosis of lung cancer is made in more than 
40% of patients aged ≥75 years (6). In 2005, Dienemann et al. 
concluded that the tumour itself rather than the age affects 
the prognosis of the octogenarian patient (7). Due to the 
large variability of comorbidities, functional performance, 
nutritional status, and social resources, which are all associated 
with aging, the patient population of over 80 years represents 
a very heterogeneous group. Significant individual variations 
of such factors are poorly represented by chronological 
age. Accordingly, the European Respiratory Society, the 
European Society of Thoracic Surgeons and the American 
College of Chest Physician recommended that the decision 
for a surgical procedure should not be based solely on the 
chronological age (2,4,8-10). Despite a large body of existing 
literature, it is still strongly debated as to which patient and 
to what extent a resection should be performed in the surgical 
management of lung cancer in patients aged over 80 years. 
To contribute to filling this knowledge gap, we here analysed 
in a tri-centre, retrospective study the mortality, morbidity, 
and the short- and long-term follow-up in octogenarians 
after curative lung resection for non-small cell lung cancer 
(NSCLC). 
Methods 
Eighty-eight consecutive patients aged between 80 and 
90 years underwent curative lung resection for NSCLC 
between 2000 and 2013. The mean age at the time of 
surgery was 82±2.0 years (range, 80–88 years), with 64 male 
(73%) and 24 female patients (27%). Perioperative risk 
was classified based on the choice of surgical procedure, 
quality of life, comorbidities, pulmonary function and 
the American Society of Anesthesiologists (ASA) score. 
Whenever possible, preoperative histological diagnosis was 
obtained by transbronchial needle biopsy, bronchoalveolar 
lavage, and bronchoscopic or computer-tomography-guided 
biopsy. Mediastinoscopy and endobronchial ultrasound 
were not applied routinely. All data were prospectively 
acquired and retrospectively analysed in three different 
thoracic departments. To obtain follow-up and survival data, 
telephone interviews were performed with the patients, 
their families or the general practitioner. Variables included 
in the database were age, sex, performance status, ASA 
score, body mass index, pulmonary function tests [forced 
expiratory volume in one second (FEV1), forced vital 
capacity (FVC) and diffusing capacity of the lung to carbon 
monoxide (DLCO)], preoperative risk factors, type of 
surgery (wedge resection, segmental resection, lobectomy, 
bilobectomy, pneumonectomy), chemotherapy treatment, 
TNM tumour classification, including histology, hospital 
stay, mortality, morbidity, follow-up and development of 
tumour-recurrence. 
Every patient gave signed informed consent prior to 
surgery which was approved by the Institutional Ethic 
Board of University of Zurich. 
Statistics
All data were analysed using the Statistical Package for 
Social Science (IBM SPSS Statistics 22 for Windows). Data 
were presented as median and range. The survival data 
were analysed using Kaplan-Meier curves and log-rank 
test. The statistical frequencies were evaluated using the 
chi square test and the Fisher’s exact test. A Cox regression 
analysis was performed to analyse factors determining 
overall survival. A P≤0.05 was considered as significant. 
Results
Patient characteristics and procedures
All 88 patients underwent lung resection with curative 
intention. The detailed surgical procedures are summarised 
in Table 1. The preferred procedure was a lobectomy or 
bilobectomy, while a pneumonectomy was performed 
only for central tumours and in patients with outstanding 
performance status (ASA 1 or 2) and respiratory function 
(both, FEV1 and DLCO ≥70%). Sublobar resection was 
performed in those patients with impaired performance 
status (> ASA 3) and severe comorbidities, or in early 
tumour-stages (cT1, cN0-1). Systematic mediastinal 
lymphadenectomy was performed on a regular basis during 
all anatomic resections. The most common comorbidities 
associated with an increased perioperative risk were the 
presence of an aortocoronary bypass in eight patients (8.8%), 
coronary heart disease in five patients (5.6%) and valvular 
heart disease in four patients (4.4%). The median FEV1, 
FVC, and DLCO were 2.00 L (range, 0.82–3.66 L), 91% 
(range, 62–158%), and 69% (range, 12–124%), respectively. 
In the studied cohort, 5 patients (5.5%) had an ASA score 
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of 1, 50 (55%) an ASA score of 2, 34 (37.3%) an ASA score 
of 3 and 2 (2.2%) an ASA score of 4. The histological 
diagnosis was defined according to the criteria of the 
World Health Organization classification for NSCLC, 
7th edition (8,11,12). Adenocarcinoma was diagnosed in 
41 patients (46.6%), squamous cell carcinoma in 33 patients 
(37.5%), large cell carcinoma in 5 patients (5.6%) and other 
histological types in 9 patients (10.2%). Regarding the final 
pathological stage, 1 patient (1.1%) presented at stage 0, 53 
(60.2%) at stage I, 17 (19.3%) at stage II and 14 (15.9%) 
at stage IIIA. The definitive histology of the patient at 
stage 0 revealed adenocarcinoma in situ. In particular, 
21 patients (24%) had a positive lymph-node stage, namely 
11 patients (12.5%) with pN1 and 10 (11.4%) with pN2 
stage. Stage pT3 was found in nine patients (10.2%) 
and pT4 in two patients (2.3%). No patient received 
neoadjuvant or adjuvant therapy due to the age with 
associated risk factors or impaired lung function.
Mortality and morbidity
The 90-day mortality was 1.1%. One patient with left-sided 
pneumonectomy died 12 days after surgery due to a 
postoperative sepsis with right-sided pneumonia, and 
pulmonary and renal failure. Conversely, 36 patients 
(40.9%) had an uneventful postoperative course. Of the 
remaining 51 patients (58%), 41 (46.6%) had only a single 
complication, 9 (10.2%) had two complications whereas 
1 (1.1%) had three complications. Postoperative pulmonary 
morbidity occurred in 22 patients (25%). In addition, 
22 patients (25%) developed cardiovascular morbidity 
requiring medical—particularly antiarrhythmic—treatment. 
Twenty-four (27%) patients displayed other complications 
(cerebrovascular incidents, urinary tract infection). The 
most frequent complications were atrial arrhythmia in 
15 patients (17%), pneumonia in 5 patients (5.6%) and 
delirium in 5 patients (5.6%) (Table 2).
Out of 88 patients, 9 (10%) were re-operated for 
haemothorax [4], persistent air leakage [3] bronchial 
stump insufficiency [1] or pneumothorax [1] within 7 days 
postoperatively. The patient with the bronchial stump 
insufficiency underwent an operative debridement and the 
stump was covered by the omentum. In the three patients with 
a prolonged air leakage, a surgical closing of the fistula with 
pulmonary sealant (fibrin glue) or direct suture was performed. 
The severity of the complications according to the Common 
Terminology Criteria for Adverse Events is presented in 
Table 3 (13). The median hospitalisation time was 10 days (range, 
5–27 days) and drainage time was 5 days (range, 0–17 days). 
Follow-up and survival
Patients were followed from their time of diagnosis (starting 
in 2001) to mid-2013. The median follow-up duration was 
27 months (range, 1–110 months). During this period, 
of the 33 patients (37.5%) who died, this was from local 
recurrences in 4 patients (4.5%), from metastases in 
4 patients (4.5%), from non-cancer specific causes in 
11 patients (12.5%) or from another malignancy in 1 patient 
(1.1%). In 13 patients (14.7%), the cause of mortality was 
undetermined. The median survival time was 40 months 
(range, 1–110 months) with overall survival rates at 1, 
3 and 5 years of 89%, 73% and 45%, respectively (Figure 1). 
Survival curves according to tumour stage and operative 
procedure are presented in Figures 2 and 3. Covariates 
influencing survival are summarised in Table 4. The only 
independent risk factor was the N-stage (P=0.045). When 
Table 1 Type of curative lung resection
Operative procedures No. of patients %
Limited resection  
(wedge-or segmentectomy)
12 13.6
Lobectomy 61 69.3
Left-sided 25
Right-sided 36
Bilobectomy 9 11
Pneumonectomy 6 6.1
Left-sided 3
Right-sided 3
Table 2 Number and type of postoperative complications
Number and type of complication No. of patients %
Overall morbidity 51 58
1 complication 41 46.6
>1 complication 10 11.4
Most frequent complications
Atrial arrhythmia 15 17
Pneumonia 5 5.6
Postoperative delirium 5 5.6
Pneumothorax 1 1.1
Haemothorax 4 4.5
Persistent air leakage 3 3.3
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Table 3 Complication classification according to the Common 
Terminology Criteria for Adverse Events (CTCAE) (Kluetz et al. 2016)
Grade No. of patients %
0 34 38.6
1 6 6.8
2 29 33
3 5 5.7
4 13 14.8
5 1 1.1
Figure 1 Overall 5-year survival in octogenarians undergoing 
curative lung resection for stages I–IV lung cancer.
Figure 2 Cumulative 5-year survival according to tumour stage in 
octogenarians undergoing curative lung resection for stages I–IV 
lung cancer.
Figure 3 Cumulative 5-year survival according to the operative 
procedure in octogenarians undergoing curative lung resection for 
stages I–IV lung cancer.
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using Cox multivariate analysis, preoperative FEV1 values 
and the overall survival were correlated. On the other hand, 
the significance was lost when the cohort was subdivided 
into subgroups based on a preoperative 80% FEV1 cut-off 
and chronic obstructive pulmonary disease (COPD) at stage 
II, respectively.
Discussion
In recent years, a series of studies have demonstrated that 
surgical treatment in selected patients older than 80 years 
can be successfully performed (2,4,7,14-21). The strength 
of the present study is, however, that we are able to show 
that such patients display very low postoperative mortality 
as well as relatively good early and long-term outcomes 
even in advanced tumour stages and an equal outcome even 
after extended resections, including pneumonectomy. 
From a prognostic point of view, pulmonary resection 
remains the best treatment modality for elderly patients 
with early stage NSCLC (13,22) provided that the mortality 
is kept low. Advances in pre- and postoperative management 
of patients, anaesthesia and surgical techniques have 
led, over recent years, to a significant reduction in the 
postsurgical mortality and morbidity and increased long-
term survival rates. Indeed, Takamochi and colleagues (16) 
demonstrated equivalent morbidity and mortality rates 
for elderly patients (over 70 years) compared to younger 
cohorts. In this series, lobectomy was performed in 
85% of the younger group of patients and in 80% of the 
elderly population. Multivariate analysis revealed that 
smoking, hypertension, renal insufficiency and DLCO 
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Table 4 Details of covariates influencing survival
Parameters Hazard ratio 95% confidence interval P value
Sex 1.3 0.28–6.22 0.71
FEV1 1.2 0.97–1.02 0.04
DLCO 0.98 0.96–1.02 0.31
ASA 0.89 0.2–3.54 0.86
Cardiac risk factors 1.6 0.5–5.1 0.42
Operative procedure 1.0 0.5–1.9 0.98
Histology 0.6 0.2–1.3 0.28
Tumor stage 0.16 0.21–1.3 0.95
T-stage – – 0.16
N-stage 0.8 0.79–1.23 0.045
Postoperative complications (all) 1.0 0.48–2.19 0.92
Pulmonary complications 1.3 0.38–4.85 0.63
FEV1, forced expiratory volume in one second; DLCO, diffusing capacity of the lung to carbon monoxide; ASA, American Society of 
Anesthesiologists.
were significant risk factors for the postoperative morbidity 
among the elderly (16). 
Since 2000, the reported perioperative mortality rates 
have ranged between 0 and 12.5%, mostly dependent on 
the distribution of TNM stages and the type of surgery 
performed (14). Compared to these data, our perioperative 
mortality of 1.1% (in patients aged ≥ 80 years) is extremely 
low. Dell'Amore et al. reported a perioperative mortality 
of 6.0 % in 83 patients older than 75 years (2). Rivera et al. 
reported a 30-day mortality of 6.5% in 622 patients aged 
over 80 years entered in the French registry (4). Shiono 
et al. reported in 2013 that no mortality occurred in 
119 patients older than 75 years (17). However, patients 
included in the final study underwent only a lobectomy, 
thus lowering the risk of operation-related mortality. 
There is a general consensus that the main causes of 
perioperative mortality are related to postoperative cardiac or 
pulmonary complications (2,4,14,16-18). In addition, there is 
broad evidence that pneumonectomy, particularly on the right 
side, is a major risk factor for perioperative mortality (2,20,21). 
We could confirm this trend of complications in as many 
as 44 patients (50%) who developed cardiac or pulmonary 
adverse reactions. Likewise, Dell'Amore et al. reported 
a morbidity rate of 48.6%, with cardiac and pulmonary 
complications, including postoperative atrial fibrillation, 
atelectasis, air leakages and prolonged ventilation, as the 
predominant causes (2). Furthermore, Takamochi et al. (16) 
described a 42% morbidity rate in 409 septuagenarians; 
again, the older cohort of patients more frequently developed 
atrial fibrillation and pneumonia during the postoperative 
period. Atrial fibrillation was also reported by Dominguez-
Ventura to be the most frequent postoperative complication 
in a population of 379 patients (18).
With regard to possible predictors of postoperative 
pulmonary morbidity in elderly patients, there are still 
some inconsistencies: Fanucchi et al. (20) reported that a 
preoperative FEV1 <1.5 L was not associated with a higher 
incidence of mortality or morbidity. In contrast, the study 
by Dell'Amore et al. (2) found FEV1 to be a risk factor for 
the perioperative mortality. Although, in our study, FEV1-
values correlated with the overall survival, the significance 
was lost when the cohort was divided into subgroups 
according to the 80% cut-off value.
With regard to postoperative long-term survival, our 
5-year survival rate matches well those of other studies 
ranging from 27% to 57.7% (2,15,17,20,21). The wide 
range of 5-year survival reported is most likely due to the 
different proportions of early and late stages of NSCLC as well 
as the extent of surgical resections. Other confounding factors 
are selection bias, limited number of patients, incomplete 
follow-up and the different interpretations of ‘elderly’ (2). The 
5-year survival reported by Dell'Amore et al. was at 38% in a 
cohort of 319 patients with a mean age of 78.1 years (2). In this 
series, 53.3% of patients had a pathological stage I and 14.7% 
a pathological stage III NSCLC. 
In addition, the long-term survival decreased significantly 
with increasing tumour stage. Furthermore, Shiono et al. (17) 
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reported a 5-year survival of 57.7% in 119 patients with a 
mean age of 77 years and a proportion of 71.4% stage I and 
15.1% stage III NSCLC. Finally, Okami et al. (15) achieved 
a 5-year survival of 55.7% in a patient population of 
367 clinical stage I patients with a mean age of 82.3 years. 
Except for patients who had stages IIA and IIIA lung 
cancer and did not survive 5 years, our data compare well 
to the general patient population (14). However, this bias in 
our study might be due to the small numbers of patients in 
these cohorts (4 in stage IIA and 14 in stage IIIA).
In our study, the type of surgical treatment, histology, 
pathologic T-stage, gender and perioperative risk factors 
showed no correlation with overall survival. Whereas 
Dienemann et al. (7) and Voltolini et al. (21) reported the 
tumour stage to be the most important prognostic factor for 
long-term survival in the elderly, we found only the N-stage 
as a significant prognostic factor. In addition to tumour 
stage, long-term survival is influenced by other factors, 
including pneumonectomy, which is a major risk factor 
for both perioperative mortality and long-term survival 
(2,18,20,21). In this context, Voltolini et al. discouraged the 
performance of pneumonectomy in octogenarians given a 
significant 25% mortality rate observed in their series (21). 
Likewise, Dell'Amore et al. (2) reported a mortality rate 
of 23.3%, with no patient reaching a survival of 5-years. 
Dominguez-Ventura et al. (18) concluded from their data 
that patients undergoing pneumonectomy had a poorer 
long-term survival, with a 10.6% 5-year survival. Accordingly, 
in our series, no patient who had pneumonectomy survived 
5 years. In contrast to Voltolini et al. (21), we attempt to avoid 
a pneumonectomy whenever possible but do not exclude 
it a priori. The statistically relevant poorer mortality and 
long-term survival rates of pneumonectomy may be partially 
explained by covarying the data with advanced tumour stages 
as described by Dominguez-Ventura et al. (18).
Maintaining the quality of life constitutes another 
important issue in octogenarians. Ferguson et al. (23) 
examined the quality of life of septuagenarians after major 
lung resection and found that this was not different in such 
patients compared to younger cohorts, despite a higher 
number of postoperative complications in the elderly 
patient population. Stereotactic radiotherapy (SBRT) is 
the mainstay of alternative therapy in patients who are 
inoperable and in those who refuse surgery, and this therapy 
could even be discussed as a curative treatment alternative 
to surgical resection (24). However, a comparison between 
surgical and radiotherapy treated patients remains difficult 
because of the lack of pathologic confirmation of the 
specimen on radiotherapy treatment. Despite SBRT being 
usually a well-tolerated treatment, it was not comparable to 
surgery in different studies (25,26). The European Society 
for medical oncology clinical guidelines consider SBRT as a 
first-line treatment in non-operable patients (27). Haasbeek 
et al. demonstrated an improvement in overall survival 
in the surgical and radiotherapy groups compared to the 
patients without treatment (25). Consequently, the decision 
to subject octogenarians to SBRT is to be made within a 
dedicated multidisciplinary team with balanced expertise. 
If possible, a pre-treatment pathological proof, preferably 
obtained by biopsy, is recommended. If this is not possible 
and if malignancy is highly likely based on the described 
criteria, immediate SBRT without histopathological 
confirmation could be a treatment option (27). 
In conclusion, our study demonstrates that curative 
lung resection should be considered in octogenarians as a 
first-line therapy. This can be performed up to the extent 
of pneumonectomy irrespective of the tumour stage, thus 
offering the best curative therapeutic modality. 
Acknowledgements
None.
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare.
Ethical Statement: Every patient gave signed informed 
consent prior to surgery which was approved by the 
Institutional Ethic Board of University of Zurich.
References
1. Pallis AG, Gridelli C, van Meerbeeck JP, et al. EORTC 
Elderly Task Force and Lung Cancer Group and 
International Society for Geriatric Oncology (SIOG) experts' 
opinion for the treatment of non-small-cell lung cancer in an 
elderly population. Ann Oncol 2010;21:692-706.
2. Dell'Amore A, Monteverde M, Martucci N, et al. Early 
and long-term results of pulmonary resection for non-
small-cell lung cancer in patients over 75 years of age: a 
multi-institutional study. Interact Cardiovasc Thorac Surg 
2013;16:250-6.
3. Yancik R, Ries LA. Aging and cancer in America. 
Demographic and epidemiologic perspectives. Hematol 
302 Tutic-Horn et al. Curative lung cancer resection in octogenarians
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(2):296-302jtd.amegroups.com
Oncol Clin North Am 2000;14:17-23.
4. Rivera C, Dahan M, Bernard A, et al. Surgical treatment 
of lung cancer in the octogenarians: results of a nationwide 
audit. Eur J Cardiothorac Surg 2011;39:981-6.
5. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv 
Exp Med Biol 2016;893:1-19.
6. Brown JS, Eraut D, Trask C, et al. Age and the treatment 
of lung cancer. Thorax 1996;51:564-8.
7. Dienemann H, Hoffmann H, Herth F. Thoracic surgery 
in the elderly. Chirurg 2005;76:126-30.
8. The World Health Organization histological typing 
of lung tumours. Second edition. Am J Clin Pathol 
1982;77:123-36.
9. Colice GL, Shafazand S, Griffin JP, et al. Physiologic 
evaluation of the patient with lung cancer being 
considered for resectional surgery: ACCP evidenced-
based clinical practice guidelines (2nd edition). Chest 
2007;132:161S-77S.
10. Brunelli A, Charloux A, Bolliger CT, et al. The European 
Respiratory Society and European Society of Thoracic 
Surgeons clinical guidelines for evaluating fitness for 
radical treatment (surgery and chemoradiotherapy) 
in patients with lung cancer. Eur J Cardiothorac Surg 
2009;36:181-4.
11. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung 
cancer staging system. Chest 2009;136:260-71.
12. Goldstraw P, Chansky K, Crowley J, et al. The IASLC 
Lung Cancer Staging Project: Proposals for Revision of 
the TNM Stage Groupings in the Forthcoming (Eighth) 
Edition of the TNM Classification for Lung Cancer. J 
Thorac Oncol 2016;11:39-51.
13. Kluetz PG, Chingos DT, Basch EM, et al. Patient-
Reported Outcomes in Cancer Clinical Trials: Measuring 
Symptomatic Adverse Events With the National Cancer 
Institute's Patient-Reported Outcomes Version of the 
Common Terminology Criteria for Adverse Events 
(PRO-CTCAE). Am Soc Clin Oncol Educ Book 
2016;35:67-73.
14. Guerra M, Neves P, Miranda J. Surgical treatment of 
non-small-cell lung cancer in octogenarians. Interact 
Cardiovasc Thorac Surg 2013;16:673-80.
15. Okami J, Higashiyama M, Asamura H, et al. Pulmonary 
resection in patients aged 80 years or over with clinical 
stage I non-small cell lung cancer: prognostic factors 
for overall survival and risk factors for postoperative 
complications. J Thorac Oncol 2009;4:1247-53.
16. Takamochi K, Oh S, Matsuoka J, et al. Risk factors for 
morbidity after pulmonary resection for lung cancer in 
younger and elderly patients. Interact Cardiovasc Thorac 
Surg 2011;12:739-43.
17. Shiono S, Abiko M, Sato T. Postoperative complications 
in elderly patients after lung cancer surgery. Interact 
Cardiovasc Thorac Surg 2013;16:819-23.
18. Dominguez-Ventura A, Cassivi SD, Allen MS, et al. Lung 
cancer in octogenarians: factors affecting long-term survival 
following resection. Eur J Cardiothorac Surg 2007;32:370-4.
19. Rocco G, Weder W. Lung surgery in the elderly today. 
Lung Cancer 2013;80:115-9.
20. Fanucchi O, Ambrogi MC, Dini P, et al. Surgical 
treatment of non-small cell lung cancer in octogenarians. 
Interact Cardiovasc Thorac Surg 2011;12:749-53.
21. Voltolini L, Rapicetta C, Ligabue T, et al. Short- and long-
term results of lung resection for cancer in octogenarians. 
Asian Cardiovasc Thorac Ann 2009;17:147-52.
22. Available online: www.cancer.org/asc/groups/cid/
documents/webcontent/003115-pdf.pdf
23. Ferguson MK, Parma CM, Celauro AD, et al. Quality of 
life and mood in older patients after major lung resection. 
Ann Thorac Surg 2009;87:1007-12; discussion 1012-3.
24. Haasbeek CJ, Lagerwaard FJ, Antonisse ME, et al. Stage 
I nonsmall cell lung cancer in patients aged &gt; or =75 
years: outcomes after stereotactic radiotherapy. Cancer 
2010;116:406-14.
25. Haasbeek CJ, Palma D, Visser O, et al. Early-stage lung 
cancer in elderly patients: a population-based study 
of changes in treatment patterns and survival in the 
Netherlands. Ann Oncol 2012;23:2743-7.
26. Gauden SJ, Tripcony L. The curative treatment by radiation 
therapy alone of Stage I non-small cell lung cancer in a 
geriatric population. Lung Cancer 2001;32:71-9.
27. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. 
Early and locally advanced non-small-cell lung cancer 
(NSCLC): ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Ann Oncol 2013;24 
Suppl 6:vi89-98.
Cite this article as: Tutic-Horn M, Gambazzi F, Rocco G, 
Mosimann M, Schneiter D, Opitz I, Martucci N, Hillinger S, 
Weder W, Jungraithmayr W. Curative resection for lung cancer 
in octogenarians is justified. J Thorac Dis 2017;9(2):296-302. 
doi: 10.21037/jtd.2017.02.22
